Why Prestige Consumer Healthcare Raised Its 2027 Outlook

Prestige Consumer Healthcare (PBH) lifted its fiscal 2027 revenue and earnings outlook on 6 August 2026, tying the higher targets to the integration of two recently acquired businesses.

The company now expects revenue between $1.29b and $1.32b, compared with an earlier range of $1.10b to $1.12b. Projected GAAP diluted EPS is set between $4.18 and $4.28.

This guidance update arrived alongside Prestige Consumer Healthcare’s first quarter results for the period ended 30 June 2026. The company reported sales of $265.71m, compared with $249.53m a year earlier.

Net income for the quarter was $29.18m, compared with $47.47m in the prior year period. Diluted EPS from continuing operations was $0.61, compared with $0.95 a year ago.

Prestige Consumer Healthcare’s latest guidance move comes after a mixed share price pattern, with a 7 day share price return of 8.97% and a 30 day share price return of 7.95% helping counter a year to date share price decline of 11.09% and a 1 year total shareholder return decline of 19.49%. This suggests recent momentum has improved even though longer term shareholders are still facing weaker outcomes.

If you are reassessing your watchlist after Prestige Consumer Healthcare’s guidance update, it can be useful to see what else is gaining attention in adjacent themes through our healthcare focused screener 42 healthcare AI stocks

For Prestige Consumer Healthcare, that sharp short term bounce contrasts with weaker 1 year and multi year returns. Is the latest move a genuine reflection of improving fundamentals, or mainly a reset in sentiment ahead of valuation work?

Most Popular Narrative: 18.5% Undervalued

Prestige Consumer Healthcare’s most followed valuation narrative puts fair value at $66.80 per share, compared with the latest close of $54.43. That gap sits on a detailed set of growth, margin and discount rate assumptions that go well beyond the near term guidance raise.

Prestige's strong and consistent free cash flow generation (~$245 million projected for the year) provides financial flexibility for continued deleveraging and opportunistic share repurchases, supporting future earnings per share (EPS) growth and value for shareholders.

Want to see what is behind that fair value gap for Prestige Consumer Healthcare? The narrative is based on steady revenue expansion, firmer margins and a future earnings multiple that differs from the broader pharmaceuticals sector. It explores which assumptions really carry the valuation story and how sensitive they are if conditions shift.

Result: Fair Value of $66.80 (UNDERVALUED)

However, Prestige Consumer Healthcare still faces supply chain recovery risk around key brands and rising e commerce competition, which could pressure pricing and long term earnings assumptions.

Next Steps

The mix of positives and concerns around Prestige Consumer Healthcare makes this a story that depends on how you weigh each side. Take a closer look at the full picture and see how the risks and potential rewards stack up in the 3 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Prestige Consumer Healthcare?

If Prestige Consumer Healthcare is on your radar after this update, it makes sense to scan for other stocks that could fit your risk, income, or value goals.

• Target potential value opportunities by checking out companies that screen as 51 high quality undervalued stocks.
• Strengthen the quality of your shortlist by reviewing the solid balance sheet and fundamentals stocks screener (49 results).
• Spot potential early stage opportunities before they gain wider attention with the screener containing 19 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.